|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PEAK1 |
Gene summary for PEAK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PEAK1 | Gene ID | 79834 |
| Gene name | pseudopodium enriched atypical kinase 1 | |
| Gene Alias | SGK269 | |
| Cytomap | 15q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9H792 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79834 | PEAK1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.19e-27 | -8.33e-01 | 0.0155 |
| 79834 | PEAK1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.51e-04 | -8.66e-01 | 0.0216 |
| 79834 | PEAK1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.10e-10 | -5.69e-01 | -0.1207 |
| 79834 | PEAK1 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.79e-06 | -3.28e-01 | -0.1464 |
| 79834 | PEAK1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.99e-03 | -6.37e-01 | -0.0179 |
| 79834 | PEAK1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.18e-17 | -7.33e-01 | 0.096 |
| 79834 | PEAK1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.46e-02 | -8.19e-01 | 0.0451 |
| 79834 | PEAK1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.17e-08 | -8.42e-01 | 0.0528 |
| 79834 | PEAK1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.65e-07 | -5.15e-01 | 0.0338 |
| 79834 | PEAK1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.72e-23 | -7.06e-01 | 0.0674 |
| 79834 | PEAK1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.35e-04 | -4.97e-01 | 0.0112 |
| 79834 | PEAK1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.11e-07 | -6.09e-01 | 0.0588 |
| 79834 | PEAK1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.02e-43 | -7.81e-01 | 0.294 |
| 79834 | PEAK1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.06e-40 | -8.08e-01 | 0.3859 |
| 79834 | PEAK1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.84e-07 | -7.54e-01 | 0.2585 |
| 79834 | PEAK1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.40e-48 | -9.23e-01 | 0.3005 |
| 79834 | PEAK1 | A002-C-010 | Human | Colorectum | FAP | 5.45e-03 | -2.39e-01 | 0.242 |
| 79834 | PEAK1 | A001-C-207 | Human | Colorectum | FAP | 8.86e-03 | -2.81e-01 | 0.1278 |
| 79834 | PEAK1 | A015-C-203 | Human | Colorectum | FAP | 4.98e-45 | -7.26e-01 | -0.1294 |
| 79834 | PEAK1 | A015-C-204 | Human | Colorectum | FAP | 1.03e-05 | -3.64e-01 | -0.0228 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000195210 | Prostate | BPH | regulation of cell-matrix adhesion | 48/3107 | 128/18723 | 9.98e-09 | 3.34e-07 | 48 |
| GO:003432910 | Prostate | BPH | cell junction assembly | 114/3107 | 420/18723 | 2.52e-08 | 7.49e-07 | 114 |
| GO:000716010 | Prostate | BPH | cell-matrix adhesion | 72/3107 | 233/18723 | 4.17e-08 | 1.16e-06 | 72 |
| GO:19018888 | Prostate | BPH | regulation of cell junction assembly | 62/3107 | 204/18723 | 6.71e-07 | 1.30e-05 | 62 |
| GO:00467778 | Prostate | BPH | protein autophosphorylation | 52/3107 | 227/18723 | 8.26e-03 | 3.59e-02 | 52 |
| GO:00344466 | Stomach | GC | substrate adhesion-dependent cell spreading | 18/1159 | 108/18723 | 1.07e-04 | 2.09e-03 | 18 |
| GO:00108106 | Stomach | GC | regulation of cell-substrate adhesion | 28/1159 | 221/18723 | 2.49e-04 | 4.17e-03 | 28 |
| GO:00315895 | Stomach | GC | cell-substrate adhesion | 40/1159 | 363/18723 | 2.91e-04 | 4.68e-03 | 40 |
| GO:01501155 | Stomach | GC | cell-substrate junction organization | 15/1159 | 101/18723 | 1.35e-03 | 1.49e-02 | 15 |
| GO:00343295 | Stomach | GC | cell junction assembly | 42/1159 | 420/18723 | 1.50e-03 | 1.62e-02 | 42 |
| GO:00070445 | Stomach | GC | cell-substrate junction assembly | 14/1159 | 95/18723 | 2.07e-03 | 2.09e-02 | 14 |
| GO:00019525 | Stomach | GC | regulation of cell-matrix adhesion | 17/1159 | 128/18723 | 2.33e-03 | 2.25e-02 | 17 |
| GO:01501165 | Stomach | GC | regulation of cell-substrate junction organization | 11/1159 | 71/18723 | 4.07e-03 | 3.41e-02 | 11 |
| GO:00071605 | Stomach | GC | cell-matrix adhesion | 25/1159 | 233/18723 | 5.24e-03 | 4.11e-02 | 25 |
| GO:003444611 | Stomach | CAG with IM | substrate adhesion-dependent cell spreading | 17/1050 | 108/18723 | 1.03e-04 | 2.28e-03 | 17 |
| GO:015011511 | Stomach | CAG with IM | cell-substrate junction organization | 15/1050 | 101/18723 | 4.93e-04 | 7.45e-03 | 15 |
| GO:000704411 | Stomach | CAG with IM | cell-substrate junction assembly | 14/1050 | 95/18723 | 8.13e-04 | 1.08e-02 | 14 |
| GO:003158911 | Stomach | CAG with IM | cell-substrate adhesion | 35/1050 | 363/18723 | 1.29e-03 | 1.53e-02 | 35 |
| GO:001081011 | Stomach | CAG with IM | regulation of cell-substrate adhesion | 24/1050 | 221/18723 | 1.50e-03 | 1.69e-02 | 24 |
| GO:015011611 | Stomach | CAG with IM | regulation of cell-substrate junction organization | 11/1050 | 71/18723 | 1.90e-03 | 2.02e-02 | 11 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PEAK1 | SNV | Missense_Mutation | rs756989281 | c.4865G>A | p.Arg1622Gln | p.R1622Q | Q9H792 | protein_coding | tolerated(0.42) | possibly_damaging(0.51) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PEAK1 | SNV | Missense_Mutation | c.4618G>A | p.Glu1540Lys | p.E1540K | Q9H792 | protein_coding | tolerated(0.13) | possibly_damaging(0.575) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PEAK1 | SNV | Missense_Mutation | novel | c.1915N>C | p.Ala639Pro | p.A639P | Q9H792 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PEAK1 | SNV | Missense_Mutation | rs781337850 | c.4726C>T | p.Arg1576Cys | p.R1576C | Q9H792 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PEAK1 | SNV | Missense_Mutation | novel | c.2651N>G | p.Asn884Ser | p.N884S | Q9H792 | protein_coding | deleterious(0.03) | benign(0.054) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| PEAK1 | SNV | Missense_Mutation | c.80A>G | p.His27Arg | p.H27R | Q9H792 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | |
| PEAK1 | SNV | Missense_Mutation | rs749774987 | c.4906N>T | p.Arg1636Trp | p.R1636W | Q9H792 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| PEAK1 | SNV | Missense_Mutation | c.73A>T | p.Ser25Cys | p.S25C | Q9H792 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD | |
| PEAK1 | SNV | Missense_Mutation | rs200619883 | c.4907G>A | p.Arg1636Gln | p.R1636Q | Q9H792 | protein_coding | tolerated(0.6) | benign(0) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PEAK1 | SNV | Missense_Mutation | c.3078G>T | p.Gln1026His | p.Q1026H | Q9H792 | protein_coding | tolerated(0.17) | benign(0.365) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |